Business
Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting
Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting.
About this update from Innovation Pharmaceuticals Inc.
[{"type":"text","content":"\n Brilacidin showed potent inhibition in multiple human cell lines and in different strains of alphaviruses and bunyaviruses, building on earlier antiviral work in coronavirusesThese data collectively support Brilacidin’s broad-spectrum antiviral potential, leveraging Brilacidin’s ability to disrupt viral integrity and block viral entry WAKEFIELD, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that new Brilacidin antiviral data, based on research conducted by George Mason University (GMU)/National Center for Biodefense and Infectious Diseases researchers, was presented yesterday, July 21, 2021, at the American Society of Virology’s 40th Annual Meeting (ASV 2021). New antiviral data included Brilacidin’s inhibition of SARS-CoV-2 in additional cell lines (Caco-2, primary lung fibroblasts), and Brilacidin’s inhibition of alphaviruses—Venezuelan Equine Encephalitis Virus, Eastern Equine Encephalitis Virus—and Rift Valley Fever Virus, a bunyavirus. A copy of the presentation is available for download (pdf) at the link below. “Brilacidin, a Host Defense Protein/Peptide Mimetic, Shows Potential as a Broad Spectrum Inhibitor of Acutely Infectious Viruses” (ASV 2021 Annual Conference, Oral Presentation)https://www.ipharminc.com/new-events-and-presentations/2021/7/21-american-society-of-virology-annual-meeting “Brilacidin continues to show a consistent ability in the laboratory to inhibit different contagious viruses, regardless of viral strain and in a cell type-independent manner,” said Aarthi Narayanan, PhD, Primary Investigator of Brilacidin at GMU. “Our scientific team looks forward to exploring Brilacidin further as we investigate the breadth of its antiviral profile.” “The COVID-19 pandemic, with infections, hospitalizations and deaths once again spiking, is a stark reminder that the world is in need of effective broad-spectrum antiviral countermeasures that can be readily deployed to help mitigate viral outbreaks,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Our Phase 2 Brilacidin clinical trial in hospitalized COVID-19 patients was fully enrolled. We remain eager to learn about B...